Literature DB >> 10736093

Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages.

O Halaas1, R Vik, A Ashkenazi, T Espevik.   

Abstract

Monocytes express cytotoxic factors of the tumour necrosis factor (TNF) ligand superfamily, including TNF and Fas ligand, both on the cell surface and in secreted form. In this report, we show that human monocytes and monocyte-derived macrophages stimulated with lipopolysaccharide (LPS) express APO2 ligand (APO2L, TRAIL), a recently discovered cytotoxic member of the TNF ligand superfamily. LPS increased the transcription of APO2L mRNA in monocytes and macrophages. Flow cytometric analysis showed low surface and high intracellular levels of APO2L, and LPS increased the expression of both. In addition, LPS increased the monocyte- and macrophage-mediated cytotoxicity against the APO2L-sensitive Jurkat and RPMI-8226 cells. Addition of the APO2L-binding decoy receptor 1 (DcR1)-Fc fusion protein inhibited the cytotoxicity by 30-70%. LPS also stimulated the release of soluble APO2L from the monocytes and macrophages. Monocytic phagocytosis of target cells was increased by LPS and partially inhibited by DcR1-Fc. Taken together, these data demonstrate a novel mechanism of cytotoxicity mediated by LPS-activated human monocytes and macrophages.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10736093     DOI: 10.1046/j.1365-3083.2000.00671.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  35 in total

Review 1.  Specific deletion of autoreactive T cells by adenovirus-transfected, Fas ligand-producing antigen-presenting cells.

Authors:  Huang-Ge Zhan; John D Mountz; Martin Fleck; Tong Zhou; Hui-Chen Hsu
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

3.  The magnitude of the T cell response to a clinically significant dose of influenza virus is regulated by TRAIL.

Authors:  Erik L Brincks; Prajwal Gurung; Ryan A Langlois; Emily A Hemann; Kevin L Legge; Thomas S Griffith
Journal:  J Immunol       Date:  2011-09-21       Impact factor: 5.422

Review 4.  Control of death receptor ligand activity by posttranslational modifications.

Authors:  R Weinlich; T Brunner; G P Amarante-Mendes
Journal:  Cell Mol Life Sci       Date:  2010-03-20       Impact factor: 9.261

5.  Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement.

Authors:  Noha A Azab; Hanaa M Rady; Samar A Marzouk
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

6.  TLR4 activates NF-κB in human ovarian granulosa tumor cells.

Authors:  Dori C Woods; Yvonne A R White; Caroline Dau; A L Johnson
Journal:  Biochem Biophys Res Commun       Date:  2011-05-17       Impact factor: 3.575

Review 7.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy.

Authors:  Silvia von Karstedt; Antonella Montinaro; Henning Walczak
Journal:  Nat Rev Cancer       Date:  2017-05-24       Impact factor: 60.716

Review 8.  TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what's new?

Authors:  Anna Neve; Addolorata Corrado; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2012-12-30       Impact factor: 3.984

Review 9.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

10.  Type I interferons and interferon regulatory factors regulate TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected macrophages.

Authors:  Yunlong Huang; Angelique Walstrom; Luwen Zhang; Yong Zhao; Min Cui; Ling Ye; Jialin C Zheng
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.